Pfenex Inc. (PFNX): Price and Financial Metrics


Pfenex Inc. (PFNX): $12.75

-0.01 (-0.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PFNX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PFNX Stock Price Chart Interactive Chart >

Price chart for PFNX

PFNX Price/Volume Stats

Current price $12.75 52-week high $14.00
Prev. close $12.76 52-week low $5.26
Day low $12.74 Volume 1,625,300
Day high $12.94 Avg. volume 503,865
50-day MA $11.26 Dividend yield N/A
200-day MA $9.82 Market Cap 437.29M

Pfenex Inc. (PFNX) Company Bio


Pfenex is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. Pfenex was founded in 2009 and was based in San Diego, California.


PFNX Latest News Stream


Event/Time News Detail
Loading, please wait...

PFNX Latest Social Stream


Loading social stream, please wait...

View Full PFNX Social Stream

Latest PFNX News From Around the Web

Below are the latest news stories about Pfenex Inc that investors may wish to consider to help them evaluate PFNX as an investment opportunity.

Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain

Business Wire | August 31, 2020

PFENEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pfenex Inc. - PFNX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pfenex Inc. (NYSE: PFNX) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of Pfenex will receive $12.00 in cash, and a one-time contingent value right of $2.00 in the event a predefined regulatory milestone is achieved by December 31, 2021, for

Business Wire | August 14, 2020

Pfenex leads healthcare gainers; Mesoblast and Genesis Healthcare among losers

Gainers: Pfenex (PFNX) +67%. Eyenovia (EYEN) +44%. ProPhase Labs (PRPH) +38%. Trevi Therapeutics (TRVI) +20%. Pieris Pharmaceuticals (PIRS) +18%.Losers: Fulcrum Therapeutics (FULC) -44%. Mesoblast (MESO) -37%. Fennec Pharmaceuticals (FENC) -35%. Genesis Healthcare (GEN) -28%. PDS Biotechnology (PDSB) -24%....

Seeking Alpha | August 11, 2020

Ligand Pharmaceuticals to acquire fellow San Diego biotech Pfenex for up to $516M

Ligand Pharmaceuticals is set to acquire Pfenex in the fourth quarter of 2020. The two San Diego biotechs rely on developing early-stage tools and licensing them out to other companies.

San Diego Union-Tribune | August 11, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc. ("PFNX" or the "Company") (NYSE American: PFNX) in connection with the proposed acquisition of the Company by…

PR Newswire | August 11, 2020

Read More 'PFNX' Stories Here

PFNX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 93.77%
5-year 207.23%
YTD N/A
2021 N/A
2020 0.00%
2019 244.20%
2018 19.92%
2017 -70.67%

Continue Researching PFNX

Here are a few links from around the web to help you further your research on Pfenex Inc's stock as an investment opportunity:

Pfenex Inc (PFNX) Stock Price | Nasdaq
Pfenex Inc (PFNX) Stock Quote, History and News - Yahoo Finance
Pfenex Inc (PFNX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7044 seconds.